DexCom commends expansion of CGM Medicare to diabetics using all insulin types

Dexcom commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events. The updated Medicare policy is the biggest single expansion of CGM coverage in the U.S. to date. Dexcom G7 sends real-time glucose readings automatically to a compatible smart device or Dexcom receiverSection, no painful fingersticks required ."This landmark CMS decision has the potential to bring Dexcom CGM to millions more Medicare patients living with diabetes," said Teri Lawver, executive vice president and chief commercial officer at Dexcom. "Our MOBILE study, which helped lead to this decision, is part of Dexcom’s ongoing efforts to help increase access to the most accurate, easy to use CGM technology that offers people a better way to manage diabetes and improve their quality of life." Results from the 2021 MOBILE study, sponsored by Dexcom and using Dexcom CGM, served as the primary piece of clinical evidence that led to this coverage expansion by demonstrating that CGM use significantly improves A1C and increases time in range for adults with Type 2 diabetes on basal insulin. This is a major win for the diabetes community, and another validation of how CGM can benefit all people living with diabetes," said Thomas Martens, MD, internal medicine physician and key MOBILE study investigator. "The evidence is clear: Real-time CGM use helps people with diabetes on all types of insulin, not just mealtime insulin, achieve better glycemic outcomes. This CMS decision is an important step forward in improving access to CGM technology, and we hope private insurers will follow."